SEARCH

SEARCH BY CITATION

References

  • Alessi D. R., Cuenda A., Cohen P., Dudley D. T. and Saltiel A. R. (1995) PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J. Biol. Chem. 270, 2748927494.
  • Banks W. A. (2004) The many lives of leptin. Peptides 25, 331338.
  • Banks A. S., Davis S. M., Bates S. H. and Myers M. G., Jr (2000) Activation of downstream signals by the long form of the leptin receptor. J. Biol. Chem. 275, 1456314572.
  • Buginai O., Giaccone G., Verga L., Pollo B., Ghetti B., Frangione B. and Tagliavini F. (1990) Alzheimer patients and Down patients: abnormal presynaptic terminals are related to cerebral preayloid deposits. Neurosci. Lett. 119, 5659.
  • Cohen B., Novick D. and Rubinstein M. (1996) Modulation of insulin activities by leptin. Science 274, 11851188.
  • Cota D., Proulx K., Smith K. A., Kozma S. C., Thomas G., Woods S. C. and Seeley R. J. (2006) Hypothalamic mTOR signaling regulates food intake. Science 312, 927930.
  • Fewlass D. C., Noboa K., Pi-Sunyer F. X., Johnston J. M., Yan S. D. and Tezapsidis N. (2004) Obesity-related leptin regulates Alzheimer's Abeta. FASEB J. 18, 18701878.
  • Frühbeck G. (2006) Intracellular signalling pathways activated by leptin. Biochem. J. 393, 720.
  • Greco S. J., Bryan K. J., Sarkar S., Zhu X., Smith M. A., Ashford J. W., Johnston J. M., Tezapsidis N. and Casadesus G. (2010) Leptin reduces pathology and improves memory in a transgenic mouse model of Alzheimer's disease. J. Alzheimers Dis. 19, 11551167.
  • Gürsel D. B., Connell-Albert Y. S., Tuskan R. G., Anastassiadis T., Walrath J. C., Hawes J. J., Amlin-Van Schaick J. C. and Reilly K. M. (2011) Control of proliferation in astrocytoma cells by the receptor tyrosine kinase/PI3K/AKT signaling axis and the use of PI-103 and TCN as potential anti-astrocytoma therapies. Neuro-oncology 13, 610621.
  • Gylys K. H., Fein J. A., Yang F., Miller C. A. and Colo G. M. (2007) Increase choresterol in Aβ-positive nerve terminals from Alzheimer's disease cortex. Neurobiol. Aging 28, 817.
  • Hay N. and Sonenberg N. (2004) Upstream and downstream of mTOR. Genes Dev. 18, 19261945.
  • Kellerer M., Koch M., Metzinger E., Mushack J., Capp E. and Haring H. U. (1997) Leptin activates PI-3 kinase in C2C12 myotubes via janus kinase-2 (JAK-2) and insulin receptor substrate-2 (IRS-2) dependent pathways. Diabetologia 40, 13581362.
  • Kim S. K., Park H. J., Hong H. S., Baik E. J., Jung M. W. and Mook-Jung I. (2006) ERK1/2 is an endogenous negative regulator of the gamma-secretase activity. FASEB J. 20, 157159.
  • Kirken R. A., Erwin R. A., Taub D., Murphy W. J., Behbod F., Wang L., Pericle F. and Farrar W. L. (1999) Tyrphostin AG-490 inhibits cytokine-mediated JAK3/STAT5a/b signal transduction and cellular proliferation of antigen-activated human T cells. J. Leukoc. Biol. 65, 891899.
  • Kojro E., Postina R., Buro C., Meiringer C., Gehrig-Burger K. and Fahrenholz F. (2006) The neuropeptide PACAP promotes the alpha-secretase pathway for processing the Alzheimer amyloid precursor protein. FASEB J. 20, 512514.
  • Kuo C. J., Chung J., Fiorentino D. F., Flanagan W. M., Blenis J. and Crabtree G. R. (1992) Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase. Nature 358, 7073.
  • Li X. L., Aou S., Oomura Y., Hori N., Fukunaga K. and Hori T. (2002) Impairment of long-term potentiation and spatial memory in leptin receptor-deficient rodents. Neuroscience 113, 607615.
  • Lieb W., Beiser A. S., Vasan R. S. et al. (2009) Association of plasma leptin levels with incident Alzheimer disease and MRI measures of brain aging. JAMA 302, 25652572.
  • Marwarha G. and Ghribi O. (2012) Leptin signaling and Alzheimer's disease. Am. J. Neurodegener. Dis. 1, 245265.
  • Marwarha G., Dasari B., Prasanthi J. R., Schommer J. and Ghribi O. (2010) Leptin reduces the accumulation of Abeta and phosphorylated tau induced by 27-hydroxycholesterol in rabbit organotypic slices. J. Alzheimers Dis. 19, 10071019.
  • Meydan N., Grunberger T., Dadi H. et al. (1996) Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 379, 645648.
  • Molander-Melin M., Blennow K., Bogdanovic N., Dellheden B., Månsson J.E. and Fredman P. (2005) Structural membrane alterations in Alzheimer brains found to be associated with regional disease development; increased density of gangliosides GM1 and GM2 and loss of cholesterol in detergent-resistant membrane domains. J Neurochem. 92, 171182.
  • Moloney A.M., Griffin R.J., Timmons S., O'Connor R., Ravid R. and O'Neill C. (2010) Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol. Aging 31, 224243.
  • Morris D. L. and Rui L. (2009) Recent advances in understanding leptin signaling and leptin resistance. Am. J. Physiol. Endocrinol. Metab. 297, E1247E1259.
  • Morrison C. D. (2009) Leptin signaling in brain: a link between nutrition and cognition? Biochim. Biophys. Acta 1792, 401408.
  • Naiki H. and Gejyo F. (1999) Kinetic analysis of amyloid fibril formation. Methods Enzymol. 309, 305318.
  • Petanceska S. S. and Gandy S. (1999) The phosphatidylinositol 3-kinase inhibitor wortmannin alters the metabolism of the Alzheimer's amyloid precursor protein. J. Neurochem. 73, 23162320.
  • Power D. A., Noel J., Collins R. and O'Neill D. (2001) Circulating leptin levels and weight loss in Alzheimer's disease patients. Dement. Geriatr. Cogn. Disord. 12, 167170.
  • Probst A., Langui D., Ipsen S., Robakis N. and Ulrich J. (1991) Deposition of beta/A4 protein along neuronal plasma membranes in diffuse senile plaques. Acta Neuropathol. 83, 2129.
  • Shineman D. W., Dain A. S., Kim M. L. and Lee V. M. (2009) Constitutively active Akt inhibits trafficking of amyloid precursor protein and amyloid precursor protein metabolites through feedback inhibition of phosphoinositide 3-kinase. Biochemistry 48, 37873794.
  • Solano D. C., Sironi M., Bonfini C., Solerte S. B., Govoni S. and Racchi M. (2000) Insulin regulates soluble amyloid precursor protein release via phosphatidyl inositol 3 kinase-dependent pathway. FASEB J. 14, 10151022.
  • Tamagno E., Guglielmotto M., Giliberto L., Vitali A., Borghi R., Autelli R., Danni O. and Tabaton M. (2009) JNK and ERK1/2 pathways have a dual opposite effect on the expression of BACE1. Neurobiol. Aging 30, 15631573.
  • Terry R. D., Peck A., DeTeresa R., Schechter R. and Horoupian D. S. (1981) Some morphometric aspects of the brain in senile dementia of the Alzheimer type. Ann. Neurol. 10, 184192.
  • Vecchione C., Maffei A., Colella S. et al. (2002) Leptin effect on endothelial nitric oxide is mediated through Akt-endothelial nitric oxide synthase phosphorylation pathway. Diabetes 51, 168173.
  • Vlahos C. J., Matter W. F., Hui K. Y. and Brown R. F. (1994) A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J. Biol. Chem. 269, 52415248.
  • Wen Y., Yu W. H., Maloney B. et al. (2008) Transcriptional regulation of beta-secretase by p25/cdk5 leads to enhanced amyloidogenic processing. Neuron 57, 680690.
  • Yamamoto N., Yoneda K., Asai K. et al. (2001) Alterations in the expression of the AQP family in cultured rat astrocytes during hypoxia and reoxygenation. Brain Res. Mol. Brain Res. 90, 2638.
  • Yamamoto N., Igbabvoa U., Shimada Y., Ohno-Iwashita Y., Kobayashi M., Wood W. G., Fujita S. C. and Yanagisawa K. (2004) Accelerated Aβ aggegation in the presence of GM1-ganglioside-accumulated synaptosomes of aged apoE4-knock-in mouse brain. FEBS Lett. 569, 135139.
  • Yamamoto N., Fukata Y., Fukata M. and Yanagisawa K. (2007) GM1-ganglioside-induced Aβ assembly on synaptic membranes of cultured neurons. Biochim. Biophys. Acta 1768, 11281137.
  • Yamamoto N., Matsubara T., Sato T. and Yanagisawa K. (2008) Age-dependent high-density clustering of GM1 ganglioside at presynaptic neuritic terminals promotes amyloid β-protein fibrillogenesis. Biochim. Biophys. Acta 1778, 27172726.
  • Yamamoto N., Taniura H. and Suzuki K. (2010) Insulin inhibits Abeta fibrillogenesis through a decrease of the GM1 ganglioside-rich microdomain in neuronal membranes. J. Neurochem. 113, 628636.
  • Yamamoto N., Matsubara T., Sobue K., Tanida M., Kasahara R., Naruse K., Taniura H., Sato T. and Suzuki K. (2012) Brain insulin resistance accelerates Aβ fibrillogenesis by inducing GM1 ganglioside clustering in the presynaptic membranes. J. Neurochem. 121, 619628.
  • Yamamoto N., Arima H., Sugiura T., Hirate H., Taniura H., Suzuki K. and Sobue K. (2013) Propofol and thiopental suppress amyloid fibril formation and GM1 ganglioside expression through the γ-aminobutyric acid A receptor. Anesthesiology 118, 14081416.
  • Yanagisawa K., Odaka A., Suzuki N. and Ihara Y. (1995) GM1 ganglioside-bound amyloid β-protein (Aβ): a possible form of preamyloid in Alzheimer's disease. Nat. Med. 1, 10621066.
  • Yanagisawa K., Fantini J., Chakrabartty A. and Eckert A. (2011) Aβ behavior on neuronal membranes: aggregation and toxicities. Int. J. Alzheimers Dis. 2011, 286536.
  • Yuyama K., Yamamoto N. and Yanagisawa K. (2006) Chloroquine-induced endocytic pathway abnormalities: cellular model of GM1 ganglioside-induced Aβ fibrillogenesis in Alzheimer's disease. FEBS Lett. 580, 69726976.